Tamtam Try Tamtam free
Noom logo

Noom account plan

AI, coaching, psychology, health

At a glance

Noom is a Princeton, NJ behavior-change health company pairing its app with GLP-1, peptide and preventive care prescriptions, consumer and enterprise.

Noom, headquartered in Princeton, NJ with an office in New York City, is a behavior change company that now pairs its app-based habit program with "prescription-grade catalysts": GLP-1 medications (including microdoses), hormonal health and peptide therapies, and at-home lab tests. It sells to consumers directly and, through Noom Health, to employers and health plans, offering "millions of Americans" metabolic health programs. In 2026 it bought a 503A compounding pharmacy, Tailor Made Compounding, and launched a second brand, OpenRx, for peptides. The documents give no revenue, profit or headcount figures.

Business units

Strategic priorities

From weight loss to preventive health and longevity
Noom is broadening beyond weight loss into healthy aging. Cook: "Weight health is the entry point to preventive care—and foundational to healthy aging", and the formulary is being widened to peptide-based therapies like sermorelin and interventions like NAD+.
Behavior change as the moat around GLP-1s
Cook cites a study in which only 8 out of 100 people were still on a GLP-1 after three years, so Noom uses the drug to spark habits that last after it. It favours low microdoses with a "low and slow" titration and says it will publish its own weight-maintenance data in 2026.
Outcomes and ROI for payers
For employers and health plans, Noom sells measured outcomes: Cook says Noom "has proven its ROI through various RCTs and whitepapers", and the Noom Band wearable is bundled into enterprise programs in 2027.
Vertical integration of clinical care, diagnostics and pharmacy
Noom describes an integrated, AI-enhanced system combining wearable-monitored behavior change, clinical care, diagnostics and pharmacy. It added at-home Tasso blood tests (17 biomarkers, every four months) to the microdose program and bought its own 503A pharmacy.
Two-brand portfolio
The flagship Noom brand deepens into cardiometabolic health, while OpenRx serves conditions such as energy, muscle composition, skin health, sexual health, sleep and recovery, referring patients to the Noom app at appropriate times.

Investments and deals

Tailor Made Compounding acquisition
Finalized April 1, 2026: Noom's first major acquisition and its largest investment to date in healthy aging (price not disclosed). TMC operates in 46 states, serves more than 400 clinics and runs a facility of more than 40,000 square feet.
Noom Band wearable
Unveiled at HLTH USA 2026 on November 16, 2026, built with Sensor Bio and launching in early 2027 for all Noom Health clients at no additional up-front cost. Noom's own data, not peer-reviewed: GLP-1 members with a connected wearable were 34% more likely to lose 20 pounds by month 4.
OpenRx launch
A new peptide and preventive health brand launched November 17, 2026, with more interventions expected in the coming months; BPC-157 and TB-500 are under review.
At-home labs in the microdose program
Tasso at-home blood collection every four months, measuring 17 biomarkers including high-sensitivity C-reactive protein and testosterone.

Challenges and risks

GLP-1 discontinuation
Patients drop off the medication: 8 out of 100 still on it after three years and 15 out of 100 at two years, per a study Cook cites, so most members eventually come off the drug.
Compounding regulation
Noom's microdose and peptide offers depend on 503A compounding rules and FDA green-listed API suppliers; Cook reads the current administration as supportive but says "you can't obviously speak for the regulator".
Branded drug pricing
Cook says GLP-1 prices were maybe $99 in London and $499 in New York; Noom ran Wall Street Journal back covers proposing a high priced drug list, saying that "at some point you're gouging the public".
Safety and compliance of new therapies
Each new compound needs safety-signal monitoring, medical-director review, a compliant supply chain and adverse event reporting before it enters the formulary, which is why BPC-157 and TB-500 are still under review.

What leadership says

“Weight health is the entry point to preventive care—and foundational to healthy aging”

Geoff Cook, CEO · Press release on the Tailor Made Compounding acquisition, April 1, 2026

“You're not going to be on this medication forever, so why dose up to a dose that potentially makes you sick and that when you then remove that food, noise, is just going to come roaring back.”

Geoff Cook, CEO · Boundless Life podcast with Ben Greenfield, January 1, 2026

“Peptides are an important portion of the formulary of healthy aging”

Geoff Cook, CEO · OpenRx launch press release, November 17, 2026

“a fitness perk that gets left in a drawer”

Cody Fair, Chief Commercial Officer, Noom Health · Noom Band press release, November 16, 2026, contrasting the device with tools that deliver outcomes

Where a supplier can help

Outcomes evidence for payers
Tied to the outcomes-and-ROI priority and the Noom Band launch: suppliers of health-economics analysis, claims data or clinical research services can help Noom Health prove ROI to employers and health plans.
Pharmacy operations and compliance
Tied to the Tailor Made Compounding acquisition, the OpenRx launch and the compounding-regulation challenge: quality, inventory, API sourcing, fulfilment and regulatory-compliance tooling for a multi-state 503A pharmacy.
Wearable and lab data integration
Tied to the vertical-integration priority: Noom Band data and Tasso lab results feed one behavior-science engine, an opening for data platforms, logistics for at-home kits and device support.
Engagement and retention across two brands
Tied to the GLP-1 discontinuation challenge and the two-brand portfolio: tools for member engagement, lifecycle messaging and cross-referral between OpenRx and the Noom app.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Noom?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Noom

What does Noom do?

Noom is a behavior change health company. Its app builds daily habits, and it pairs them with prescriptions such as GLP-1 microdoses and peptides, plus at-home lab tests, for consumers and, through Noom Health, for employers and health plans.

Who leads Noom?

Geoff Cook is CEO. Dr. Jeffrey Egler is Chief Medical Officer and Cody Fair is Chief Commercial Officer of Noom Health.

What is Noom's strategy?

To move from weight loss into preventive health and longevity, using behavior change as the moat around GLP-1 and peptide treatments, integrating wearables, diagnostics and its own pharmacy, and selling measured ROI to payers.

What did Noom acquire in 2026?

Tailor Made Compounding, a licensed 503A pharmacy operating in 46 states, finalized on April 1, 2026. It is Noom's first major acquisition.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-19)